Insilico Medicine, whose Hong Kong IPO application lapsed in 2024, is still considering going public in the city, said ...

The New Normal Five years ago, COVID-19 was declared a global pandemic, marking the official onset of a healthcare crisis ...

Pheiron and Ribo are excited to announce that the first two strategic collaboration milestones have been successfully ...

The Chinese health care technology sector is in the midst of a transformative phase, fueled by breakthroughs in artificial ...

Orphan Drug Designation follows positive Phase 1 data presented at the 12th International Workshop on Waldenström ...

Eradivir, a clinical-stage small molecule immunotherapy biotech company, announced it has begun a Phase 2 challenge study with its antiviral therapeutic, EV25. The study will provide safety and ...

For more information on the Phase 1b clinical trial, visit: https://clinicaltrials.gov/study/NCT06732180 ...

Empire Discovery Institute (EDI), a leading non-profit drug discovery and development accelerator, is pleased to announce the appointment of Dr. Ronald Newbold as Chief Executive Officer (CEO).  Dr.

The European Medicines Agency and Belgium’s Federal Agency for Medicines and Health Products have approved a Phase 2 challenge study on EV25, an antiviral therapeutic from Eradivir. The approval ...

As the field of regenerative medicine continues to advance, the incorporation of AI is playing a transformative role in the pharmaceutical industry.

Explore why Recursion Pharmaceuticals' AI-driven drug discovery faces challenges in revenue growth, governance, and investor ...